This report contains market size and forecasts of Ventilator Associated Pneumonia (VAP) Therapeutics in Global, including the following market information:
Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Ventilator Associated Pneumonia (VAP) Therapeutics market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ventilator Associated Pneumonia (VAP) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ventilator Associated Pneumonia (VAP) Therapeutics Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Segment Percentages, By Type, 2020 (%)
- Prevention
- Physiotherapy
- Immunity Therapy
China Ventilator Associated Pneumonia (VAP) Therapeutics Market, By Application, 2016-2021, 2022-2027 ($ millions)
China Ventilator Associated Pneumonia (VAP) Therapeutics Market Segment Percentages, By Application, 2020 (%)
- Hospitals
- Ambulatory Surgical Center
- Diagnostic Centers
Global Ventilator Associated Pneumonia (VAP) Therapeutics Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Segment Percentages, By Region and Country, 2020 (%)
- North America
- - US
- - Canada
- - Mexico
- Europe
- - Germany
- - France
- - U.K.
- - Italy
- - Russia
- - Nordic Countries
- - Benelux
- - Rest of Europe
- Asia
- - China
- - Japan
- - South Korea
- - Southeast Asia
- - India
- - Rest of Asia
- South America
- - Brazil
- - Argentina
- - Rest of South America
- Middle East & Africa
- - Turkey
- - Israel
- - Saudi Arabia
- - UAE
- - Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Total Ventilator Associated Pneumonia (VAP) Therapeutics Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Ventilator Associated Pneumonia (VAP) Therapeutics Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
- Achaogen
- Adenium Biotech
- Aridis Pharmaceuticals
- AstraZeneca
- Bayer
- Cardeas Pharma
- Destiny Pharma
- Dong-A Socio Holdings
- Lakewood-Amedex
- MedImmune
- Meiji Seika Pharma
- Merck & Co
- Motif Bio
- Nabriva Therapeutics
- Polyphor
- Shionogi & Co
- Tetraphase Pharmaceuticals
- The Medicines Company
- Theravance Biopharma
- Wockhardt
- Zavante Therapeutics
Ventilator Associated Pneumonia (VAP) Therapeutics Market - Global Outlook and Forecast 2021-2027
Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Overall Market Size
2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size: 2021 VS 2027
2.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Ventilator Associated Pneumonia (VAP) Therapeutics Players in Global Market
3.2 Top Global Ventilator Associated Pneumonia (VAP) Therapeutics Companies Ranked by Revenue
3.3 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Ventilator Associated Pneumonia (VAP) Therapeutics Companies in Global Market, by Revenue in 2020
3.5 Global Companies Ventilator Associated Pneumonia (VAP) Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Ventilator Associated Pneumonia (VAP) Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Ventilator Associated Pneumonia (VAP) Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Ventilator Associated Pneumonia (VAP) Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Markets, 2021 & 2027
4.1.2 Prevention
4.1.3 Physiotherapy
4.1.4 Immunity Therapy
4.2 By Type - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2021
4.2.2 By Type - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2022-2027
4.2.3 By Type - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2021 & 2027
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Center
5.1.4 Diagnostic Centers
5.2 By Application - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2021
5.2.2 By Application - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2022-2027
5.2.3 By Application - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2021 & 2027
6.2 By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2021
6.2.2 By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2022-2027
6.2.3 By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2027
6.3.2 US Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.3.3 Canada Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.3.4 Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2027
6.4.2 Germany Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.4.3 France Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.4.4 U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.4.5 Italy Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.4.6 Russia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.4.7 Nordic Countries Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.4.8 Benelux Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2027
6.5.2 China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.5.3 Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.5.4 South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.5.5 Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.5.6 India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2027
6.6.2 Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.6.3 Argentina Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2027
6.7.2 Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.7.3 Israel Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.7.4 Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
6.7.5 UAE Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, 2016-2027
7 Players Profiles
7.1 Achaogen
7.1.1 Achaogen Corporate Summary
7.1.2 Achaogen Business Overview
7.1.3 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.1.4 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.1.5 Achaogen Key News
7.2 Adenium Biotech
7.2.1 Adenium Biotech Corporate Summary
7.2.2 Adenium Biotech Business Overview
7.2.3 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.2.4 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.2.5 Adenium Biotech Key News
7.3 Aridis Pharmaceuticals
7.3.1 Aridis Pharmaceuticals Corporate Summary
7.3.2 Aridis Pharmaceuticals Business Overview
7.3.3 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.3.4 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.3.5 Aridis Pharmaceuticals Key News
7.4 AstraZeneca
7.4.1 AstraZeneca Corporate Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.4.4 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.4.5 AstraZeneca Key News
7.5 Bayer
7.5.1 Bayer Corporate Summary
7.5.2 Bayer Business Overview
7.5.3 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.5.4 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.5.5 Bayer Key News
7.6 Cardeas Pharma
7.6.1 Cardeas Pharma Corporate Summary
7.6.2 Cardeas Pharma Business Overview
7.6.3 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.6.4 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.6.5 Cardeas Pharma Key News
7.7 Destiny Pharma
7.7.1 Destiny Pharma Corporate Summary
7.7.2 Destiny Pharma Business Overview
7.7.3 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.4.4 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.7.5 Destiny Pharma Key News
7.8 Dong-A Socio Holdings
7.8.1 Dong-A Socio Holdings Corporate Summary
7.8.2 Dong-A Socio Holdings Business Overview
7.8.3 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.8.4 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.8.5 Dong-A Socio Holdings Key News
7.9 Lakewood-Amedex
7.9.1 Lakewood-Amedex Corporate Summary
7.9.2 Lakewood-Amedex Business Overview
7.9.3 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.9.4 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.9.5 Lakewood-Amedex Key News
7.10 MedImmune
7.10.1 MedImmune Corporate Summary
7.10.2 MedImmune Business Overview
7.10.3 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.10.4 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.10.5 MedImmune Key News
7.11 Meiji Seika Pharma
7.11.1 Meiji Seika Pharma Corporate Summary
7.11.2 Meiji Seika Pharma Business Overview
7.11.3 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.11.4 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.11.5 Meiji Seika Pharma Key News
7.12 Merck & Co
7.12.1 Merck & Co Corporate Summary
7.12.2 Merck & Co Business Overview
7.12.3 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.12.4 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.12.5 Merck & Co Key News
7.13 Motif Bio
7.13.1 Motif Bio Corporate Summary
7.13.2 Motif Bio Business Overview
7.13.3 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.13.4 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.13.5 Motif Bio Key News
7.14 Nabriva Therapeutics
7.14.1 Nabriva Therapeutics Corporate Summary
7.14.2 Nabriva Therapeutics Business Overview
7.14.3 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.14.4 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.14.5 Nabriva Therapeutics Key News
7.15 Polyphor
7.15.1 Polyphor Corporate Summary
7.15.2 Polyphor Business Overview
7.15.3 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.15.4 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.15.5 Polyphor Key News
7.16 Shionogi & Co
7.16.1 Shionogi & Co Corporate Summary
7.16.2 Shionogi & Co Business Overview
7.16.3 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.16.4 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.16.5 Shionogi & Co Key News
7.17 Tetraphase Pharmaceuticals
7.17.1 Tetraphase Pharmaceuticals Corporate Summary
7.17.2 Tetraphase Pharmaceuticals Business Overview
7.17.3 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.17.4 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.17.5 Tetraphase Pharmaceuticals Key News
7.18 The Medicines Company
7.18.1 The Medicines Company Corporate Summary
7.18.2 The Medicines Company Business Overview
7.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.18.4 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.18.5 The Medicines Company Key News
7.19 Theravance Biopharma
7.19.1 Theravance Biopharma Corporate Summary
7.19.2 Theravance Biopharma Business Overview
7.19.3 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.19.4 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.19.5 Theravance Biopharma Key News
7.20 Wockhardt
7.20.1 Wockhardt Corporate Summary
7.20.2 Wockhardt Business Overview
7.20.3 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.20.4 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.20.5 Wockhardt Key News
7.21 Zavante Therapeutics
7.21.1 Zavante Therapeutics Corporate Summary
7.21.2 Zavante Therapeutics Business Overview
7.21.3 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Major Product Offerings
7.21.4 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (2016-2021)
7.21.5 Zavante Therapeutics Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Ventilator Associated Pneumonia (VAP) Therapeutics Market Opportunities & Trends in Global Market
Table 2. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers in Global Market
Table 3. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints in Global Market
Table 4. Key Players of Ventilator Associated Pneumonia (VAP) Therapeutics in Global Market
Table 5. Top Ventilator Associated Pneumonia (VAP) Therapeutics Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Share by Companies, 2016-2021
Table 8. Global Companies Ventilator Associated Pneumonia (VAP) Therapeutics Product Type
Table 9. List of Global Tier 1 Ventilator Associated Pneumonia (VAP) Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ventilator Associated Pneumonia (VAP) Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2022-2027
Table 30. Achaogen Corporate Summary
Table 31. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 32. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 33. Adenium Biotech Corporate Summary
Table 34. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 35. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 36. Aridis Pharmaceuticals Corporate Summary
Table 37. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 38. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 39. AstraZeneca Corporate Summary
Table 40. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 41. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 42. Bayer Corporate Summary
Table 43. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 44. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 45. Cardeas Pharma Corporate Summary
Table 46. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 47. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 48. Destiny Pharma Corporate Summary
Table 49. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 50. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 51. Dong-A Socio Holdings Corporate Summary
Table 52. Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 53. Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 54. Lakewood-Amedex Corporate Summary
Table 55. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 56. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 57. MedImmune Corporate Summary
Table 58. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 59. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 60. Meiji Seika Pharma Corporate Summary
Table 61. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 62. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 63. Merck & Co Corporate Summary
Table 64. Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 65. Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 66. Motif Bio Corporate Summary
Table 67. Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 68. Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 69. Nabriva Therapeutics Corporate Summary
Table 70. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 71. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 72. Polyphor Corporate Summary
Table 73. Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 74. Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 75. Shionogi & Co Corporate Summary
Table 76. Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 77. Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 78. Tetraphase Pharmaceuticals Corporate Summary
Table 79. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 80. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 81. The Medicines Company Corporate Summary
Table 82. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 83. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 84. Theravance Biopharma Corporate Summary
Table 85. Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 86. Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 87. Wockhardt Corporate Summary
Table 88. Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 89. Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
Table 90. Zavante Therapeutics Corporate Summary
Table 91. Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Product Offerings
Table 92. Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (US$, Mn), (2016-2021)
List of Figures
Figure 1. Ventilator Associated Pneumonia (VAP) Therapeutics Segment by Type
Figure 2. Ventilator Associated Pneumonia (VAP) Therapeutics Segment by Application
Figure 3. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2020
Figure 8. By Type - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 9. By Application - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 10. By Region - Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 11. By Country - North America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 12. US Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 16. Germany Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 17. France Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 24. China Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 28. India Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 30. Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share, 2016-2027
Figure 33. Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Ventilator Associated Pneumonia (VAP) Therapeutics Revenue, (US$, Mn), 2016-2027
Figure 37. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 49. Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 50. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 51. Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 52. Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 53. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 54. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 55. Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 56. Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 57. Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029
Published: 11-Jan-2024 Price: US 3350 Onwards Pages: 118
The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029.
Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029.
Report Scope
This report aims to provide a comprehensive presentation of the glo......
Global Non-imaging Diagnostic Catheter Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 95
The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Imaging Diagnostic Catheter Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 90
The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......
Global PCR Equipment Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 77
The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030.
PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers:
Advancements in Research and Diagnost......
Global Disposable Sterile Syringes and Needles Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 109
The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030.
North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Disposable Sterile Syringes and N......
Global Orthopaedic Power Tools Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030.
North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......
Global Cerebrospinal Fluid Management Devices Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......
Global CAD & CAM Milling Burs Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 79
The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......
Global Artificial Teeth Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 98
The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
